Sermorelin vs CJC-1295 vs Tesamorelin
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
Sermorelin | CJC-1295 | Tesamorelin | |
|---|---|---|---|
| What it is | Growth-hormone-boosting peptide that prompts the pituitary gland; previously approved for childhood growth hormone deficiency. | Experimental long-acting peptide that raises growth hormone (GH) levels; only small studies in humans. | Approved medicine for HIV-related lipodystrophy that reduces the belly fat around internal organs. |
| Type | Shortened version of growth hormone-releasing hormone (GHRH) | Modified growth hormone-releasing hormone, long-acting | Modified version of growth hormone-releasing hormone (GHRH) |
| Structure | Fragment of GHRH made of its first 29 amino acids | 30 aa + DAC (maleimidopropionyl-D-Lys) | trans-3-hexenoyl-hGRF(1-44)NH₂ |
| Molecular weight | ~3358 Da | ~3647 Da (DAC) / ~3367 Da (no-DAC) | ~5135 Da |
| Target area | GH/IGF-1 | GH/IGF-1 | Visceral fat (HIV lipodystr.) |
| Storage | 2–8°C (reconstituted) | 2–8°C (reconstituted) | 2–8°C (reconstituted) |
| Stability | 14–21 days (reconstituted) | 25–30 days (reconstituted) | ~7 days (per label) |
| Full entry | Open → | Open → | Open → |
Sermorelin, CJC-1295 or Tesamorelin: how do they differ?
All three are versions of growth hormone-releasing hormone (GHRH), and all three prompt the pituitary gland to make growth hormone. They differ in structure: sermorelin is the stretch made of the first 29 amino acids of GHRH; CJC-1295 was altered so that it binds to one of the proteins in the blood, which is why it acts for days instead of minutes; tesamorelin is a stabilised, modified version of GHRH. Their status differs as well: the FDA previously approved sermorelin for growth hormone deficiency in children and approved tesamorelin in 2010 to reduce abdominal fat around the internal organs in HIV-associated lipodystrophy, while CJC-1295 is experimental, with only a few small human studies. The target row of the table reflects this: GH/IGF-1 for sermorelin and CJC-1295, fat around the internal organs for tesamorelin.


